Mandana Khalili, MD

School of Medicine
1001 Potrero Ave, SFGH 5
San Francisco, CA 94110
Mandana Khalili
Education and Training

University of Ottawa, M.D. - 1992 Medicine

McGill University, Gastroenterology - 1997 Gastroenterology

Ochsner Clinic, Hepatology - 1998 Hepatology

UCSF, Transplant Hepatology - 1999 Transplant Hepatology and Post-Doctoral Research

UCSF, M.A.S - 2005 Masters in Advanced Studies in Clinical and Epidemiologic Research

UCSF, Mentor Development Program Certificate - 2007 Research Mentoring

University of California San Francisco, 2022 Diversity, Equity, and Inclusion Champion Training

Awards and Honors

J.W. McConnell Entrance Award, McGill University, 1986

Natural Sciences and Engineering Research Council Award, Canada, 1988

American Digestive Health Foundation, Martin Brotman Training and Transition Award, Gastroenterology Research Group, 2000

Recognizing Discovery and Innovation in 2001: Milestones in Hepatitis C, Hepatitis Innovation Award, Schering Oncology, 2001

Longitudinal Clinical Experience Appreciation Certificate, UCSF, 2008

UCSF University Community Partnerships Council Service Learning Award, UCSF, 2009

Academic Senate Distinction in Mentoring Award Nomination, UCSF, 2013

Mid-Career Investigator Award in Patient Oriented Research, NIH, 2014

Academic Senate Distinction in Mentoring Award Nomination, UCSF, 2015

ZSFG Distinction in Medical Education Award Nomination, UCSF, 2016

Harold L. Luft Award, Health Disparity Mentoring Award Nomination, UCSF, 2017

Certificate of Appreciation-Mentor Training Program, Peking Union Medical College, Beijing, China, 2018

Visiting Professor, Department of Scientific Research, Peking Union Medical College, Beijing, China, 2019

Zuckerberg San Francisco DOM Physician COVID-19 Clinical Service Recognition Award, UCSF, 2022
Chief of Clinical Hepatology, San Francisco General Hospital
Director, Clinical and Translational Research in Hepatology, San Francisco General Hospital
Director, Investigator Development Unit, UCSF Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases (Health Equity Action Network)
Co-Director, UCSF Mentor Training Program
Co-Director, UCSF T32 Hepatology Training Program
Editorial board member, Hepatology Journal

Mandana Khalili is a Professor of Medicine in the Department of Medicine and Chief of Clinical Hepatology at Zuckerberg San Francisco General Hospital (ZSFG). She also serves as the Director of Clinical and Translational Research in Hepatology at ZSFG. Her research focuses on assessing and addressing health disparities related to viral hepatitis, nonalcoholic fatty liver disease, alcohol-associated liver disease, cirrhosis, and hepatocellular carcinoma including natural history, pathogenesis, metabolic complications, healthcare access and novel treatments. She has a longstanding track record of extramural funding in these areas and has served as PI or co-PI of several NIH-sponsored national and international networks. She currently serves as a PI for the NIDDK-sponsored Liver Cirrhosis Network and also Hepatitis B Research Network assessing the natural history and optimal management of patients with hepatitis B and cirrhosis. Her group previously evaluated mechanisms of insulin resistance and secretion in Latinos with and without hepatitis C infection and is now examining how alcohol affects insulin action and adipose tissue insulin resistance among this at high-risk populations. In collaboration with two VA hospitals, she is evaluating the impact of COVID pandemic and transitions in care delivery on telemedicine satisfaction, quality of life, cirrhosis management, liver cancer screening and substance use among vulnerable populations in order to implement measures and policies to provide equitable liver care. Her group is also evaluating alcohol treatment in patients with liver disease using a novel stepped care motivational interviewing and addiction medicine treatment in the hepatology setting. Additional studies involve hepatitis B, hepatitis C, and liver cancer screening practices and treatment in vulnerable populations receiving care in safety net setting and those experiencing homelessness; aimed at establishing policies to enhance hepatitis B and C elimination efforts. She has been examine knowledge attitudes and barriers to viral hepatitis and fatty liver disease management and implementing novel patient-centered and provider interventions such as education through mobile app to enhance knowledge and motivation and address barriers to care. She is a member of the Liver Cancer San Francisco Cancer Initiative (SF-CAN), which in partnership with the City and County of San Francisco and other health and community partners, is using interventional strategies to reduce cancer in the city. Her group’s recent efforts in developing an integrated model of shelter-based hepatitis C screening and treatment within large homeless shelters in San Francisco and Minnesota has been successful in scaling up hepatitis C management in persons who inject drugs and homeless residents. Dr. Khalili is passionate about mentoring trainees and junior faculty and she has mentored numerous trainee and faculty at all career stages. She is a recipient of a NIH-sponsored K24 award in mentoring junior investigators in liver disease and the co-Director (co-PI) of the T32 Training in Hepatology. She has campus wide leadership roles in mentoring as the Director of UCSF Mentor Training Program. She currently serves as the Director of Investigator Development Unit of the Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases sponsored by NIMHD. Her diverse research program including translational research, natural history and epidemiology, community/participatory research, health services, and clinical trials provides the infrastructure for supporting junior investigators and in transitioning them to independence.